• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

女性非吸烟亚洲肺腺癌患者的驱动基因突变分析。

Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.

机构信息

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine Cancer Institute, Tongji University, No 507 Zhengmin Road, Shanghai 200433, People's Republic of China.

出版信息

Cell Biochem Biophys. 2012 Nov;64(2):155-60. doi: 10.1007/s12013-012-9384-8.

DOI:10.1007/s12013-012-9384-8
PMID:22707299
Abstract

Previous studies have revealed that EGFR mutation and/or EML4-ALK gene fusion rate was higher in the non-smoker Asian females with pulmonary adenocarcinoma. The aim of this study is to determine the distribution of known oncogenic driver mutations in the female non-smoker Asian patients with pulmonary adenocarcinoma. 104 consecutively resected lung adenocarcinomas from 396 non-smoker females (less than 100 cigarettes in a lifetime) at a single institution (Tongji University, Shanghai, China) were analyzed for mutations in EGFR, EML4-ALK, KRAS, HER2, BRAF, and PIK3CA. 73 (70.2 %) tumors harbored EGFR mutations; among these, 28 were deletions in exon 19, 44 were L858R missense changes, and eight were T790M mutations. 10 (9.6 %) harbored EML4-ALK fusions, two harbored KRAS mutations, two harbored BRAF mutations, and two harbored PI3K mutations. A majority of the mutations were mutually exclusive, except two with EGFR mutation and BRAF mutation, one with EML4-ALK fusions and PI3K mutation. Thus, 82.7 % (86 of 104; 95 % CI, 75.4-90.0 %) of lung adenocarcinomas from non-smoker females were found to harbor the well-known oncogenic mutations in five genes. Lung cancer in non-smoking Asian females is a distinct entity, with majority of this subgroup being developed by the oncogenic mutations. The prospective mutation examination in this population will be helpful for devising a targeted therapy for a majority of the patients.

摘要

先前的研究表明,非吸烟的亚洲女性肺腺癌患者中 EGFR 突变和/或 EML4-ALK 基因融合率较高。本研究旨在确定女性非吸烟亚洲肺腺癌患者中已知致癌驱动基因突变的分布。对一家机构(中国上海同济大学)连续切除的 396 例非吸烟女性(终生吸烟少于 100 支)的 104 例肺腺癌进行 EGFR、EML4-ALK、KRAS、HER2、BRAF 和 PIK3CA 基因突变分析。73 例(70.2%)肿瘤存在 EGFR 突变;其中 28 例为 19 外显子缺失,44 例为 L858R 错义改变,8 例为 T790M 突变。10 例(9.6%)存在 EML4-ALK 融合,2 例存在 KRAS 突变,2 例存在 BRAF 突变,2 例存在 PI3K 突变。大多数突变是相互排斥的,除了 2 例存在 EGFR 突变和 BRAF 突变,1 例存在 EML4-ALK 融合和 PI3K 突变。因此,82.7%(104 例中的 86 例;95%CI,75.4-90.0%)的非吸烟女性肺腺癌存在 5 个基因中的已知致癌突变。不吸烟的亚洲女性肺癌是一个独特的实体,大多数亚组由致癌突变引起。对该人群进行前瞻性突变检测将有助于为大多数患者制定靶向治疗方案。

相似文献

1
Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.女性非吸烟亚洲肺腺癌患者的驱动基因突变分析。
Cell Biochem Biophys. 2012 Nov;64(2):155-60. doi: 10.1007/s12013-012-9384-8.
2
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.东亚从不吸烟人群的肺腺癌是一种主要由可靶向的致癌基因突变激酶定义的疾病。
J Clin Oncol. 2010 Oct 20;28(30):4616-20. doi: 10.1200/JCO.2010.29.6038. Epub 2010 Sep 20.
3
Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.吸烟者肺腺癌中明确的致癌驱动基因突变的频率因组织学亚型和分级吸烟剂量而异。
Lung Cancer. 2013 Jan;79(1):8-13. doi: 10.1016/j.lungcan.2012.09.018. Epub 2012 Oct 23.
4
Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.中国肺腺癌患者中表皮生长因子受体(EGFR)、棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶(EML4-ALK)、 Kirsten大鼠肉瘤病毒癌基因(KRAS)和肝细胞生长因子受体(c-MET)突变分析
Exp Lung Res. 2013 Oct;39(8):328-35. doi: 10.3109/01902148.2013.819535. Epub 2013 Aug 6.
5
Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.台湾初治肺腺癌患者中五个驱动基因突变的鉴定
PLoS One. 2015 Mar 19;10(3):e0120852. doi: 10.1371/journal.pone.0120852. eCollection 2015.
6
Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.不同临床分期非小细胞肺癌患者中的致癌驱动基因突变。
Ann Oncol. 2013 May;24(5):1319-25. doi: 10.1093/annonc/mds626. Epub 2012 Dec 30.
7
Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.208 例中国非小细胞肺癌患者中 EML4-ALK 融合基因的临床意义及其与 EGFR 和 KRAS 基因突变的关系。
PLoS One. 2013;8(1):e52093. doi: 10.1371/journal.pone.0052093. Epub 2013 Jan 14.
8
[Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].基于2011年国际多学科肺腺癌分类的分子改变在肺腺癌组织病理学亚型中的相关性
Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):505-10. doi: 10.3760/cma.j.issn.0529-5807.2012.08.001.
9
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.肺癌突变联盟中携带BRAF突变的肺腺癌患者的临床病理特征及预后
Cancer. 2015 Feb 1;121(3):448-56. doi: 10.1002/cncr.29042. Epub 2014 Oct 1.
10
Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR.从不吸烟的亚洲女性肺癌是由致癌突变驱动的,其中最常见的是涉及表皮生长因子受体(EGFR)。
Oncotarget. 2015 Mar 10;6(7):5465-74. doi: 10.18632/oncotarget.2925.

引用本文的文献

1
Cancer Among Asian Americans and Pacific Islanders, 1999-2020.1999 - 2020年亚裔美国人和太平洋岛民中的癌症情况
J Racial Ethn Health Disparities. 2025 Jul 2. doi: 10.1007/s40615-025-02517-3.
2
Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China.非小细胞肺癌中HER2外显子20突变的基因组和临床特征:来自中国南方一项多中心研究的见解
BMC Cancer. 2025 Apr 22;25(1):752. doi: 10.1186/s12885-025-14125-9.
3
Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer.
遗传背景对非小细胞肺癌 KRAS 突变及等位基因特异性亚型发生率的影响超过种族/民族因素。
HGG Adv. 2024 Jul 18;5(3):100320. doi: 10.1016/j.xhgg.2024.100320. Epub 2024 Jun 19.
4
Chinese never smokers with adenocarcinoma of the lung are younger and have fewer lymph node metastases than smokers.中国非吸烟的肺腺癌患者比吸烟患者更年轻,且淋巴结转移更少。
Respir Res. 2022 Oct 29;23(1):293. doi: 10.1186/s12931-022-02199-z.
5
Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles.评估洛杉矶一所大型学术机构中 NSCLC 患者的西班牙裔和亚裔之间的真实世界突变差异。
Clin Lung Cancer. 2022 Nov;23(7):e443-e452. doi: 10.1016/j.cllc.2022.06.007. Epub 2022 Jul 4.
6
Preparation and identification of an anti-idiotypic antibody antagonist (FG8) for EGFR that shows potential activity against liver cancer cells.制备并鉴定一种针对表皮生长因子受体(EGFR)的抗独特型抗体拮抗剂(FG8),该拮抗剂对肝癌细胞具有潜在的活性。
Biotechnol Lett. 2021 Feb;43(2):369-382. doi: 10.1007/s10529-020-03017-6. Epub 2020 Nov 3.
7
Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion.ALK变异对具有致癌性ALK融合的晚期非小细胞肺癌患者脑转移和治疗反应的影响。
Transl Lung Cancer Res. 2020 Aug;9(4):1452-1463. doi: 10.21037/tlcr-19-346.
8
Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua.非小细胞肺癌(NSCLC)的基因谱:金华的一项基于医院的调查。
Mol Genet Genomic Med. 2020 Sep;8(9):e1398. doi: 10.1002/mgg3.1398. Epub 2020 Jul 12.
9
Clinical characteristics and work-up of small to intermediate-sized pulmonary nodules in a Chinese dedicated cancer hospital.中国癌症专科医院中小至中等大小肺结节的临床特征和检查。
Cancer Biol Med. 2020 Feb 15;17(1):199-207. doi: 10.20892/j.issn.2095-3941.2019.0028.
10
Clinicopathological and Prognostic Significance of Rearrangement in Patients with Surgically Resected Lung Adenocarcinoma: A Propensity Score Matching Study.手术切除的肺腺癌患者重排的临床病理特征及预后意义:一项倾向评分匹配研究
Cancer Manag Res. 2020 Jan 24;12:589-598. doi: 10.2147/CMAR.S229217. eCollection 2020.